Dr Reddy's share price jumped almost 4% during Wednesday’s trading session after Nuvama Institutional Equities, a brokerage firm, raised its rating on the stock from ‘Reduce’ to ‘Buy,’ setting a target price of ₹1,553. The brokerage noted that the expiration of the Revlimid patent in 2026 presents a considerable risk to Dr Reddy's earnings growth, as the medication accounts for …
Indian pharma companies have long been key providers of generic medicines to the US market, accounting for 47% of all generic prescriptions in 2022, according to a recent report by the IQVIA Institute. Branded for growth Mankind Pharma Ltd, which earns 91% of its revenue from its domestic business and has a prescriber penetration rate of almost 84% as of …
